![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ARHGAP45 |
Gene summary for ARHGAP45 |
![]() |
Gene information | Species | Human | Gene symbol | ARHGAP45 | Gene ID | 23526 |
Gene name | Rho GTPase activating protein 45 | |
Gene Alias | HA-1 | |
Cytomap | 19p13.3 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q92619 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23526 | ARHGAP45 | HCC2 | Human | Liver | HCC | 1.61e-04 | 1.32e+00 | 0.5341 |
23526 | ARHGAP45 | HCC5 | Human | Liver | HCC | 1.37e-02 | 1.24e+00 | 0.4932 |
23526 | ARHGAP45 | S015 | Human | Liver | HCC | 1.08e-05 | 2.41e-01 | 0.2375 |
23526 | ARHGAP45 | S016 | Human | Liver | HCC | 1.19e-05 | 1.77e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | ![]() |
Stomach | SIM | ![]() |
Liver | NAFLD | ![]() |
Liver | Cirrhotic | ![]() |
Liver | HCC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARHGAP45 | SNV | Missense_Mutation | c.1796N>G | p.Asp599Gly | p.D599G | Q92619 | protein_coding | deleterious(0.01) | possibly_damaging(0.724) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ARHGAP45 | SNV | Missense_Mutation | rs376691391 | c.658G>A | p.Glu220Lys | p.E220K | Q92619 | protein_coding | deleterious(0.03) | possibly_damaging(0.871) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ARHGAP45 | SNV | Missense_Mutation | novel | c.758N>A | p.Gly253Glu | p.G253E | Q92619 | protein_coding | deleterious(0.02) | possibly_damaging(0.76) | TCGA-LL-A6FP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ARHGAP45 | deletion | Frame_Shift_Del | c.3046delN | p.Pro1016ArgfsTer35 | p.P1016Rfs*35 | Q92619 | protein_coding | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | |||
ARHGAP45 | SNV | Missense_Mutation | novel | c.1681N>T | p.Arg561Cys | p.R561C | Q92619 | protein_coding | deleterious(0) | probably_damaging(0.916) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ARHGAP45 | SNV | Missense_Mutation | novel | c.2887N>G | p.Thr963Ala | p.T963A | Q92619 | protein_coding | deleterious(0.05) | probably_damaging(0.998) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
ARHGAP45 | SNV | Missense_Mutation | novel | c.3225G>C | p.Gln1075His | p.Q1075H | Q92619 | protein_coding | tolerated_low_confidence(0.06) | benign(0.007) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ARHGAP45 | SNV | Missense_Mutation | c.595N>G | p.Leu199Val | p.L199V | Q92619 | protein_coding | tolerated(0.27) | probably_damaging(0.959) | TCGA-JW-A69B-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ARHGAP45 | SNV | Missense_Mutation | novel | c.1678G>A | p.Val560Met | p.V560M | Q92619 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-MA-AA3W-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ARHGAP45 | SNV | Missense_Mutation | c.1726N>C | p.Glu576Gln | p.E576Q | Q92619 | protein_coding | deleterious(0.04) | benign(0.391) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |